NFL Biosciences SA (EPA:ALNFL)

France flag France · Delayed Price · Currency is EUR
1.046
+0.006 (0.58%)
Apr 28, 2026, 5:14 PM CET
-30.27%
Market Cap 13.26M
Revenue (ttm) 188.00
Net Income (ttm) -3.32M
Shares Out 12.67M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,516
Average Volume 26,771
Open 1.026
Previous Close 1.040
Day's Range 0.990 - 1.054
52-Week Range 0.851 - 1.850
Beta 1.21
RSI 38.34
Earnings Date Apr 15, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 5
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

Financial Performance

In 2025, NFL Biosciences's revenue was 188, an increase of 308.70% compared to the previous year's 46. Losses were -3.32 million, 59.5% more than in 2024.

Financial Statements

News

There is no news available yet.